CU20210021A7 - Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias - Google Patents

Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Info

Publication number
CU20210021A7
CU20210021A7 CU2021000021A CU20210021A CU20210021A7 CU 20210021 A7 CU20210021 A7 CU 20210021A7 CU 2021000021 A CU2021000021 A CU 2021000021A CU 20210021 A CU20210021 A CU 20210021A CU 20210021 A7 CU20210021 A7 CU 20210021A7
Authority
CU
Cuba
Prior art keywords
vaccine compositions
treatment
growth factors
inflammatory diseases
hematopoietic growth
Prior art date
Application number
CU2021000021A
Other languages
English (en)
Inventor
Morales Dasha Fuentes
Valcarcel Jesus Ramón Galvez
Dávila Agustín Bienvenido Lage
Naranjo Nuris Ledón
Medianilla Armando López
Alfaro Oscar Otero
Yáñez Karla Pereira
Martínez Dayana Pérez
Dorantes Gertrudis Rojas
Hernandez Danay Saavedra
Sosa Alexa Silva
Formigo Gisela María Suárez
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Priority to CU2021000021A priority Critical patent/CU20210021A7/es
Priority to BR112023019112A priority patent/BR112023019112A2/pt
Priority to JP2023560805A priority patent/JP2024512762A/ja
Priority to CN202280025278.7A priority patent/CN117120079A/zh
Priority to KR1020237037217A priority patent/KR20230163506A/ko
Priority to EP22718850.5A priority patent/EP4316510A1/en
Priority to PCT/CU2022/050002 priority patent/WO2022207016A1/es
Priority to AU2022251604A priority patent/AU2022251604A1/en
Priority to CA3213763A priority patent/CA3213763A1/en
Priority to ARP220100643A priority patent/AR125149A1/es
Priority to TW111110599A priority patent/TW202302623A/zh
Publication of CU20210021A7 publication Critical patent/CU20210021A7/es
Priority to CONC2023/0014267A priority patent/CO2023014267A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>La presente invención se relaciona con la rama de la Biotecnología y la Medicina. Específicamente describe composiciones vacunales terapéuticas capaces de producir una reacción autoinmune contra factores de crecimiento hematopoyéticos como el G-SCF y/o GM-CSF unidas por conjugación química o fusión a otras moléculas o partes de ella. Dichas composiciones vacunales son útiles en el tratamiento de enfermedades inflamatorias, en especial donde ocurra una elevación patológica de neutrófilos circulantes.</p>
CU2021000021A 2021-03-30 2021-03-30 Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias CU20210021A7 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CU2021000021A CU20210021A7 (es) 2021-03-30 2021-03-30 Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias
EP22718850.5A EP4316510A1 (en) 2021-03-30 2022-03-16 Vaccine compositions depleting hematopoietic growth factors for the treatment of inflammatory diseases
JP2023560805A JP2024512762A (ja) 2021-03-30 2022-03-16 炎症性疾患の治療のための造血増殖因子枯渇ワクチン組成物
CN202280025278.7A CN117120079A (zh) 2021-03-30 2022-03-16 用于治疗炎性疾病的造血生长因子耗竭疫苗组合物
KR1020237037217A KR20230163506A (ko) 2021-03-30 2022-03-16 염증성 질병 치료용 조혈 성장 인자를 고갈시키는 백신 조성물
BR112023019112A BR112023019112A2 (pt) 2021-03-30 2022-03-16 Composições de vacinas depletantes de fatores de crescimento hematopoiético para o tratamento de doenças inflamatórias
PCT/CU2022/050002 WO2022207016A1 (es) 2021-03-30 2022-03-16 Composiciones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias
AU2022251604A AU2022251604A1 (en) 2021-03-30 2022-03-16 Vaccine compositions depleting hematopoietic growth factors for the treatment of inflammatory diseases
CA3213763A CA3213763A1 (en) 2021-03-30 2022-03-16 Vaccine compositions depleting hematopoietic growth factors for the treatment of inflammatory diseases
ARP220100643A AR125149A1 (es) 2021-03-30 2022-03-18 Composiciones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias
TW111110599A TW202302623A (zh) 2021-03-30 2022-03-22 用於治療發炎性疾病之造血生長因子耗盡之疫苗組成物
CONC2023/0014267A CO2023014267A2 (es) 2021-03-30 2023-10-24 Composiciones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2021000021A CU20210021A7 (es) 2021-03-30 2021-03-30 Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Publications (1)

Publication Number Publication Date
CU20210021A7 true CU20210021A7 (es) 2022-11-07

Family

ID=81387253

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000021A CU20210021A7 (es) 2021-03-30 2021-03-30 Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Country Status (12)

Country Link
EP (1) EP4316510A1 (es)
JP (1) JP2024512762A (es)
KR (1) KR20230163506A (es)
CN (1) CN117120079A (es)
AR (1) AR125149A1 (es)
AU (1) AU2022251604A1 (es)
BR (1) BR112023019112A2 (es)
CA (1) CA3213763A1 (es)
CO (1) CO2023014267A2 (es)
CU (1) CU20210021A7 (es)
TW (1) TW202302623A (es)
WO (1) WO2022207016A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
WO2010124163A2 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
CN110382532B (zh) * 2017-02-07 2023-04-14 Me医疗公司 抗g-csf抗体及其用途
US10870703B2 (en) 2017-10-02 2020-12-22 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
US20210009677A1 (en) 2018-03-23 2021-01-14 Csl Limited Method of treating asthma
CA3119192A1 (en) 2018-12-04 2020-06-11 CSL Innovation Pty Ltd Method of treating neutrophilic conditions

Also Published As

Publication number Publication date
CO2023014267A2 (es) 2024-02-05
AU2022251604A1 (en) 2023-10-26
AR125149A1 (es) 2023-06-14
KR20230163506A (ko) 2023-11-30
CN117120079A (zh) 2023-11-24
BR112023019112A2 (pt) 2023-10-24
CA3213763A1 (en) 2022-10-06
JP2024512762A (ja) 2024-03-19
WO2022207016A1 (es) 2022-10-06
TW202302623A (zh) 2023-01-16
EP4316510A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
CR11817A (es) Anticuerpos anti-factor d humanizados y sus usos
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
CL2018001414A1 (es) Anticuerpos contra cd73 y sus usos (divisional solicitud 201701296)
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
CY1123549T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
PE20151495A1 (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
PE20170071A1 (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas
AR063760A1 (es) Anticuerpos anti-factor d humanizados y usos de los mismos
BR112013031084A2 (pt) meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas
EA201691196A1 (ru) Ингибиторы тропомиозин-зависимых киназ (trk)
CO2023018231A2 (es) Restos de administración terapéutica novedosos y usos de estos
CU20210021A7 (es) Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias
SI2970447T1 (en) PROTITELES AGAINST PAN-ELR + CXC KEMOCIN
CO2022015202A2 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
CL2023000630A1 (es) Anticuerpos anti-ceacam5 y sus conjugados y usos.
AR094292A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
MX353394B (es) Aplicación de dihidroxiclorinas beta-funcionalizadas para tfd.
GB201212111D0 (en) Vascular bed-specific endothelial cells
BR112022002149A2 (pt) Composição adequada para transfectar uma molécula de ácido nucleico em uma célula, métodos para transfecção in vitro ou ex vivo de células vivas e para a produção e usos in vitro ou ex vivo da composição
UY28647A1 (es) Compuestos de amida del ácido 3-amino-tieno(2,3-b)piridin-2-carboxílico sustituido y procedimientos para su preparación y sus usos
AR105257A1 (es) Moléculas de fusión que tiene especificidad de unión a pioverdina y pioquelina
AR110424A1 (es) Moléculas de unión a adam9 y métodos de uso de las mismas
BR112013029902A2 (pt) produção de alta pureza de proteínas de múltiplas subunidades, tal como anticorpos, em micróbios transformados, tal como pichia pastoris
MX2022014384A (es) Oligonucleotidos multimericos unidos ortogonalmente.